论文部分内容阅读
目的 探讨多药耐药蛋白(P-170)在乳腺癌中的作用和地位。方法 采用免疫细胞化学染色法,检洲了33例(初治21例和复发12例)乳腺癌患者血液中的多药耐药蛋白(P-170)的表达,并进行了比较。结果 初治的乳腺癌P-170蛋白阳性表达率为14.29％,复发的乳腺癌P-170蛋白阳性表达为58.33％(P<0.01),有显著性差异,P-170蛋白检测方法具有更强 的敏感性。结论 复发组比初治组具有更普遍的抗药性,且主要是获得性抗药,P-170蛋白表达可作为临床合理地制定化疗方案,预洲化疗效果的重要参考指标。
Objective To investigate the role and status of multidrug resistance protein (P-170) in breast cancer. Methods Immunocytochemical staining was used to detect the expression of multidrug resistance protein (P-170) in 33 cases of breast cancer patients (21 untreated and 12 relapsed) and compared with each other. Results The positive rate of P-170 protein in newly diagnosed breast cancer was 14.29%, and the positive rate of P-170 protein in recurrent breast cancer was 58.33% (P <0.01), with significant difference Sensitivity. Conclusion The recurrence group has more general resistance than the initial treatment group, and is mainly acquired drug resistance. The expression of P-170 protein may be an important reference index for establishing the chemotherapy regimen and pre-chemotherapy effect clinically and rationally.